新日本製薬 estimates consolidated ordinary profit for the current fiscal year at ¥5.43 billion, up 4% from the previous period, while raising the previous period’s annual dividend to ¥59 and indicating a policy of increasing the current period’s dividend to ¥60. Ordinary profit in the latest fourth quarter was ¥1.39 billion, with revenue and the operating profit margin also improving significantly.
新日本製薬 indicated that consolidated ordinary profit for the fiscal year ending September 2026 is expected to reach ¥5.2 billion, up 6.7% from the previous period and marking an 11th consecutive record high. Revenue is expected to remain on an upward trend, and the company explained that it has a structure in place to sustain profit growth.
Consolidated ordinary profit for the fiscal year ending September 2027 is expected to be ¥5.43 billion, up 4.4% from the previous period, with the company aiming to update its full-year performance. In the latest three-month period, July–September, ordinary profit rose 45.4% year on year to ¥1.39 billion, while the ratio of operating profit to revenue improved from 8.6% to 12.7%.
For dividends, the company raised the previous period’s annual dividend to ¥59 and announced a policy of increasing the current period’s dividend to ¥60. This indicates an intention to maintain and expand the consolidated dividend payout ratio.